JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $105
Buy Rating for Janux Therapeutics Amidst Competitive Landscape and Advancements in Masked T-cell Engagers
Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer -- Barrons.com
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
LifeSci Capital Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $100
Clear Street Launches Healthcare & Biotechnology Equity Research